HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takefumi Oizumi Selected Research

Etidronic Acid (HEDP)

1/2020[Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
1/2017Inflammatory Effects of Nitrogen-Containing Bisphosphonates (N-BPs): Modulation by Non-N-BPs.
1/2016A Strategy against the Osteonecrosis of the Jaw Associated with Nitrogen-Containing Bisphosphonates (N-BPs): Attempts to Replace N-BPs with the Non-N-BP Etidronate.
10/2013Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
6/2013In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
5/2010Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
4/2010Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takefumi Oizumi Research Topics

Disease

9Inflammation (Inflammations)
01/2021 - 05/2009
6Osteonecrosis (Kienbock's Disease)
01/2020 - 05/2009
4Necrosis
01/2019 - 05/2009
3Infections
01/2020 - 06/2013
3Bone Resorption
01/2017 - 06/2013
2Osteoporosis
01/2020 - 04/2010
1Adenocarcinoma
06/2013
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/2013
1Osteomyelitis
11/2010
1Fever (Fevers)
11/2010
1Arthritis (Polyarthritis)
06/2010
1Hypersensitivity (Allergy)
06/2010
1Chronic Disease (Chronic Diseases)
06/2010
1Experimental Arthritis
06/2010

Drug/Important Bio-Agent (IBA)

8Diphosphonates (Bisphosphonates)IBA
01/2021 - 04/2010
7Etidronic Acid (HEDP)FDA LinkGeneric
01/2020 - 04/2010
5NitrogenIBA
01/2021 - 04/2010
5Clodronic Acid (Clodronate)IBA
01/2020 - 05/2009
4LipopolysaccharidesIBA
01/2021 - 06/2010
4Zoledronic Acid (Zometa)FDA Link
10/2013 - 05/2009
3Interleukin-1 (Interleukin 1)IBA
01/2021 - 06/2010
2Phosphate Transport Proteins (Phosphate Transporter)IBA
01/2021 - 01/2020
2CytokinesIBA
01/2021 - 01/2019
2Durapatite (Hydroxylapatite)IBA
05/2010 - 05/2009
1Purinergic P2X7 ReceptorsIBA
01/2021
1InterleukinsIBA
01/2021
1Adenosine Triphosphate (ATP)IBA
01/2021
1A-factor (Streptomyces)IBA
01/2019
1FoscarnetFDA LinkGeneric
01/2017
1NickelIBA
06/2010
1AntigensIBA
06/2010
1EnzymesIBA
06/2010
1Histamine (Histamine Dihydrochloride)FDA Link
06/2010
1Histidine DecarboxylaseIBA
06/2010
1AutoantigensIBA
06/2010
1Lipoproteins (Lipoprotein)IBA
06/2010
1MetalsIBA
06/2010
11''- phosphocholine- 2''- aminodihydroxypropane- 3''- phospho- 6'- glucopyranosyl- (1'- 3)- 1,2- dipalmitoylglycerolIBA
06/2010
1Toll-Like Receptor 2IBA
06/2010
1Alendronate (Alendronate Sodium)FDA LinkGeneric
05/2009
1Drug CombinationsIBA
05/2009
1Risedronic Acid (Actonel)FDA LinkGeneric
05/2009
1Pamidronate (Aredia)FDA LinkGeneric
05/2009

Therapy/Procedure

2Drug Substitution
05/2010 - 05/2009
1Subcutaneous Injections
05/2009